Longer-form write-ups of what comes out of the lab: what a pre-print or paper shows, why we built a tool the way we did, and what we are still working out. Each post links to related social media posts and papers/pre-prints.
Longer-form write-ups of what comes out of the lab: what a pre-print or paper shows, why we built a tool the way we did, and what we are still working out. Each post links to related social media posts and papers/pre-prints.
Children with brain tumors are monitored mostly by MRI, and a scan cannot always show early enough that a tumor is growing back. Circulating tumor DNA (ctDNA) is the small fraction of cell-free DNA (cfDNA) in blood and cerebrospinal fluid (CSF) that comes from the tumor. It could add a molecular readout, but pediatric brain tumors shed little of it, and laboratories define a positive sample in different ways. In our new preprint with colleagues at Phoenix Children’s, led by Shea Gallus and Sharvari Mankame, we combine three ways of detecting ctDNA into one score.
Glioblastoma is monitored mostly by MRI, which can miss early changes in tumor burden. Cell-free DNA (cfDNA) in blood is a promising alternative, but we know little about what governs its release. In our new paper in Neuro-Oncology, led by Sharvari Mankame, we dissect cfDNA release in patient-derived glioblastoma models under tightly controlled conditions.